Literature DB >> 23813506

Crohn's disease unmasked following etanercept treatment for ankylosing spondylitis.

H Jethwa1, S Mann.   

Abstract

We describe the case of a 45-year-old man with ankylosing spondylitis being treated with etanercept who presented with a 1 month history of abdominal pain. CT abdomen revealed an ileocaecal mass associated with an abscess, resulting in a laparotomy and right hemi-colectomy. Histology of the resected specimen showed the classical features of Crohn's disease. Etanercept was stopped and he was started on adalimumab. He is currently in clinical remission from both ankylosing spondylitis and Crohn's disease.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23813506      PMCID： PMC3703022          DOI： 10.1136/bcr-2013-009166

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  8 in total

Review 1.  Crohn's disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature.

Authors:  V Wiegering; H Morbach; A Dick; H J Girschick
Journal:  Rheumatol Int       Date:  2009-06-09       Impact factor: 2.631

Review 2.  Ankylosing spondylitis and bowel disease.

Authors:  Martin Rudwaleit; Dominique Baeten
Journal:  Best Pract Res Clin Rheumatol       Date:  2006-06       Impact factor: 4.098

3.  Development of Crohn's disease in a patient taking etanercept.

Authors:  Jenny Oh; Daniel G Arkfeld; David A Horwitz
Journal:  J Rheumatol       Date:  2005-04       Impact factor: 4.666

4.  Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.

Authors:  J Brandt; J Listing; H Haibel; H Sörensen; A Schwebig; M Rudwaleit; J Sieper; J Braun
Journal:  Rheumatology (Oxford)       Date:  2004-11-23       Impact factor: 7.580

5.  Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.

Authors:  W J Sandborn; S B Hanauer; S Katz; M Safdi; D G Wolf; R D Baerg; W J Tremaine; T Johnson; N N Diehl; A R Zinsmeister
Journal:  Gastroenterology       Date:  2001-11       Impact factor: 22.682

6.  New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.

Authors:  In-Ho Song; Heiner Appel; Hildrun Haibel; Christoph Loddenkemper; Jurgen Braun; Joachin Sieper; Martin Rudwaleit
Journal:  J Rheumatol       Date:  2008-01-15       Impact factor: 4.666

7.  Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action.

Authors:  Boulos Haraoui; Marilyn Krelenbaum
Journal:  Semin Arthritis Rheum       Date:  2008-08-15       Impact factor: 5.532

8.  Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.

Authors:  John C Davis; Désirée Van Der Heijde; Jurgen Braun; Maxime Dougados; John Cush; Daniel O Clegg; Alan Kivitz; Roy Fleischmann; Robert Inman; Wayne Tsuji
Journal:  Arthritis Rheum       Date:  2003-11
  8 in total
  3 in total

1.  Inflammatory Bowel Disease Provoked by Etanercept: Report of 443 Possible Cases Combined from an IBD Referral Center and the FDA.

Authors:  Aoibhlinn O'Toole; Matthew Lucci; Joshua Korzenik
Journal:  Dig Dis Sci       Date:  2016-01-04       Impact factor: 3.199

Review 2.  Etanercept-induced Crohn's disease in ankylosing spondylitis: a case report and review of the literature.

Authors:  Sena Tolu; Aylin Rezvani; Nurbanu Hindioglu; Merve Calkin Korkmaz
Journal:  Rheumatol Int       Date:  2018-10-06       Impact factor: 2.631

3.  Clinical features of Crohn disease concomitant with ankylosing spondylitis: A preliminary single-center study.

Authors:  Song Liu; Jie Ding; Meng Wang; Wanqing Zhou; Min Feng; Wenxian Guan
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.